InvestorsHub Logo
Followers 834
Posts 119885
Boards Moderated 17
Alias Born 09/05/2002

Re: DewDiligence post# 961

Thursday, 10/07/2021 9:38:35 AM

Thursday, October 07, 2021 9:38:35 AM

Post# of 1162
BMY’s Deucravacitinib fails phase-2 trial in UC:

https://finance.yahoo.com/news/bristol-myers-squibb-provides-phase-105900443.html

"While we did not achieve proof of concept in this study, we are committed to advancing our deucravacitinib clinical program in inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, as well as in psoriatic arthritis, lupus and other immune-mediated diseases.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News